|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
High LINC00096 expression was obviously related to advanced tumor stage, metastasis, poor prognosis of patients.
|
31819536 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
TP53TG1 is a recently identified lncRNA and several studies have shown that TP53TG1 may play the role of tumor suppressor gene or oncogene in different tumors.
|
31325400 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Moreover, TP53TG1 and some tumor glucose metabolism related genes, such as GRP78, LDHA, and IDH1 were up-regulated significantly in U87 and LN18 cells under glucose deprivation.
|
28569381 |
2017 |
|
Neoplasms
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
TP53TG1 hypermethylation in primary tumors is shown to be associated with poor outcome.
|
27821766 |
2016 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of TP53TG1 inhibited proliferation, induced apoptosis, and decreased migration and invasion in PDAC cells, whereas enhanced expression of TP53TG1 had the opposite effects.
|
31325400 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
LINC00096 Promotes the Proliferation and Invasion by Sponging miR-383-5p and Regulating RBM3 Expression in Triple-Negative Breast Cancer.
|
31819536 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Nevertheless, the involvement of TP53TG1 in carcinogenesis of pancreatic ductal adenocarcinoma (PDAC) has not been characterized.
|
31325400 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the involvement of TP53TG1 in carcinogenesis of pancreatic ductal adenocarcinoma (PDAC) has not been characterized.
|
31325400 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these observations imply that TP53TG1 contributes to the growth and progression of PDAC by acting as a competing endogenous RNA (ceRNA) to competitively bind to miR-96 and regulate KRAS expression, which highlights the importance of the complicated miRNA-lncRNA network in modulating the progression of PDAC.
|
31325400 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our present study, we identify LINC00096 as one of the most upregulated lncRNA in TNBC progression by using microarray screening.
|
31819536 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our present study, we identify LINC00096 as one of the most upregulated lncRNA in TNBC progression by using microarray screening.
|
31819536 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, little is known about the detailed function and molecular mechanism of TP53TG1 in cisplatin resistance of NSCLC.
|
29588850 |
2018 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
LncRNA-TP53TG1 Participated in the Stress Response Under Glucose Deprivation in Glioma.
|
28569381 |
2017 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The epigenetic loss of TP53TG1 therefore represents an altered event in an lncRNA that is linked to classical tumoral pathways, such as p53 signaling, but is also connected to regulatory networks of the cancer cell.
|
27821766 |
2016 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
The epigenetic loss of TP53TG1 therefore represents an altered event in an lncRNA that is linked to classical tumoral pathways, such as p53 signaling, but is also connected to regulatory networks of the cancer cell.
|
27821766 |
2016 |